The University of Texas at Austin
Jennifer Maynard
200 E. Dean Keeton St.
Department of Chemical Engineering, UT Austin
Austin, TX 78712
https://biologics.utexas.edu/research/advanced-protein-therapeutics-core
RRID: RRID:SCR_023740
Antibody Characterization
Antibody Development
Antibody Drug Conjugates
Antibody Engineering
Antibody Production
Antibody Sequencing
Bispecific Antibodies
Cell Culture
Cell Imaging
Confocal Microscopy
ELISA
Enzyme Engineering
Flow Cytometric Analysis
Fluorescence Spectroscopy
High-throughput Screening
Nanobody Production
Protein Extraction/Purification
Protein Production
SDS-PAGE
1.) Siles Alvarado N, Schuler M, Maguire C, Amengor DA, Nguyen AW, Wilen RE, Rogers J, Bazzi S, Caslin B, DiPasquale C, Abigania M, Olson E, Creaturo J, Hurley K, Triplett TA, Rousseau JF, Strakowski SM, Wylie D, Maynard JA, Ehrlich LIR, Melamed E (2025 May 2). SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamics. Communications medicine, 5(1), 149. . PMID: 40316665.
2.) Goldsmith JA, Nguyen AW, Wilen RE, Wijagkanalan W, McLellan JS, Maynard JA (2025 Apr 8). Structural basis for neutralizing antibody binding to pertussis toxin. Proceedings of the National Academy of Sciences of the United States of America, 122(14), e2419457122. . PMID: 40172968.
3.) Ma MT, Qerqez AN, Hill KR, Azouz LR, Youngblood HA, Hill SE, Ku Y, Peters DM, Maynard JA, Lieberman RL (2025 Jan). Antibody-mediated clearance of an ER-resident aggregate that causes glaucoma. PNAS nexus, 4(1), pgae556. . PMID: 39726989.
The UT Austin CPRIT-funded Advanced Protein Therapeutics Core (APT) catalyzes the translation of scientific discoveries into novel protein cancer therapies. We offer therapeutic antibody and enzyme discovery, engineering, and optimization services.
